Palladium Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Palladium Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-300	Closed	-$24K	–	602
2013 Q2	$24K	Buy	+300	New	+$22.1K	﹤0.01%	407

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Palladium Partners's VRTX Position: Q3 2013 in Review

Palladium Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2013, closing a stake of 300 shares — an estimated $24K sold.

Palladium Partners first reported a position in VRTX in Q2 2013 and held it in 1 quarter. The position peaked at $24K in Q2 2013. 403 funds tracked by Wall St. Rank hold VRTX as of Q3 2013.

Palladium Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
Palladium Partners sold 300 Vertex Pharmaceuticals shares in Q3 2013, an estimated $24K.
Palladium Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 1 quarter.
Palladium Partners's Vertex Pharmaceuticals position peaked at $24K in Q2 2013.
403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2013.

Based on Palladium Partners's 13F filing for Q3 2013, filed 24 Oct 2013.